Research programme: infectious diseases therapy - Innate Pharma

Drug Profile

Research programme: infectious diseases therapy - Innate Pharma

Alternative Names: IPH 1201; IPH 12XX programme - Innate Pharma

Latest Information Update: 19 Jan 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioAgency AG
  • Developer Innate Pharma
  • Class Antivirals; Phosphonic acids; Small molecules
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Hepatitis C; Parasitic infections; Tuberculosis; Viral infections

Most Recent Events

  • 19 Jan 2009 IPH 1201 is still in preclinical development for Hepatitis C in France
  • 07 Nov 2007 This programme is still in active development
  • 03 Oct 2006 Preclinical trials in Hepatitis C treatment in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top